Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

11.13 +0.75 (+7.23%)
Streaming Delayed Price Updated: 12:53 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Earnings Scheduled For March 10, 2025
Via Benzinga
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
The company is working on a treatment for non-muscle invasive bladder cancer. 
Via Investor's Business Daily
Earnings Outlook For UroGen Pharma
Via Benzinga
Earnings Scheduled For May 12, 2025
Via Benzinga
A Look at UroGen Pharma's Upcoming Earnings Report
Via Benzinga
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer. 
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Recap: UroGen Pharma Q3 Earnings
Via Benzinga
Preview: UroGen Pharma's Earnings
Via Benzinga
The Latest Analyst Ratings for UroGen Pharma
Via Benzinga
Where UroGen Pharma Stands With Analysts
Via Benzinga
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
Via Benzinga
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of... 
Via Benzinga
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil. 
Via Benzinga
Topics ETFs
$10 Trillion Added In Market Cap; 2023’s Best And Worst Through July
The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. 
Via Talk Markets
Why Shares of UroGen Pharma Jumped Friday
The company released positive top-line results for two studies for a bladder cancer treatment. 
Via The Motley Fool
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash... 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.